市場調查報告書
商品編碼
1629886
全球即時檢測設備市場 - 2025-2033Global Point-of-Care Testing Devices Market - 2025-2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2024年,全球即時檢測設備市場規模達到497.3億美元,預估至2033年將達到1,015.1億美元,2025-2033年預測期間複合年成長率為8.6%。
照護端測試 (POCT) 是在患者照護端或附近進行的醫療診斷測試,可提供快速結果,有助於治療決策。這種策略與標準實驗室測試不同,標準實驗室測試通常涉及將樣本運送到中心實驗室並等待數小時或數天才能得到結果。 POCT 的根本目的是透過提供即時資訊來改善患者管理,從而實現更快的診斷和治療。 POCT 涵蓋廣泛的測試方法和技術,例如手持式電子設備、測試套件和攜帶式分析儀。常見的例子有血糖監測、快速鏈球菌檢測和妊娠檢測。這些設備可用於各種場所,包括醫院、診所、藥局甚至家庭,使醫療保健更加便利和有效率。 POCT 技術取得了巨大的發展,儀器尺寸不斷縮小,儀器性能得到增強,準確性和易用性不斷提高。
技術進步是預測期內推動市場的促進因素。例如,Masimo 宣布 MightySat Medical 已獲得 FDA 批准,使其成為第一個也是唯一一個獲得 FDA 批准的醫用指尖脈搏血氧儀,無需處方即可向消費者提供非處方藥 (OTC)。此次批准為客戶提供了 Masimo SET 脈搏血氧儀支援的脈搏血氧儀醫療設備,世界各地的醫院和診所每年都使用同樣的技術來監測超過 2 億患者。
驅動程式和限制
技術進步
技術進步預計將成為全球即時檢測設備市場成長的重要因素。技術進步預計將對全球即時檢測(POCT)設備市場的擴張產生重大影響。隨著醫療保健的發展,對快速、準確且易於存取的診斷解決方案的需求日益成長。生物感測器、微流體和晶片實驗室系統等眾多技術的創新改變了診斷方法,使其更有效率和可靠。例如,2024 年9 月,雅培實驗室(Abbott Laboratories) 宣布其非處方連續血糖監測儀Lingo 在美國上市。正常值時就會出現血糖峰值。
此外,DEXIS 於 2024 年 8 月推出了 DEXIS Connect Pro,這是一個針對 DEXIS CBCT 和口內感測器設備的新型主動服務平台,專注於增加設備的正常運行時間。這個獨特的平台使用物聯網 (IoT) 技術來持續檢查這些設備的運作狀況,確保它們以最佳效能運作。 DEXIS Connect Pro 旨在透過自動識別潛在困難並根據需要安排支援或設備更換來顯著提高設備正常運行時間,這對於依賴一致操作來提供患者護理的牙科診所至關重要。
此外,Bio-Rad Laboratories 於 2024 年 4 月推出了首款超靈敏多重數位 PCR 檢測,即 ddPLEX ESR1 突變檢測試劑盒。該測定增加了該公司在癌症行業的液滴數位 PCR (ddPC) 產品組合,其中極其靈敏的多重突變檢測測定可增強轉化研究、藥物選擇和疾病監測。這些最近的推出和 FDA 的批准以及最新的技術進步使得診斷結果高效、快速,從而推動了市場。
初始投資成本高
初始投資成本高等因素預計將阻礙全球即時檢測設備市場。儘管 POCT 具有多種優勢,例如快速得出結果以及能夠在傳統實驗室環境之外進行測試,但與購買這些設備相關的財務成本可能會阻礙醫療機構使用它們。 POCT 設備的初始投資可能很大,尤其是對於有望提高診斷能力的先進技術。在醫療保健資金緊張的資源有限環境中,這種財務負擔尤其嚴重,使得機構難以優先投資新型診斷方法。
The global point-of-care testing devices market reached US$ 49.73 billion in 2024 and is expected to reach US$ 101.51 billion by 2033, growing at a CAGR of 8.6% during the forecast period 2025-2033.
Point-of-Care Testing (POCT) is medical diagnostic testing that is performed at or near the patient's point of care, providing for quick outcomes that may assist in treatment decisions. This strategy differs from standard laboratory testing, which frequently involves transporting samples to central labs and waiting hours or days for findings. The fundamental purpose of POCT is to improve patient management by giving immediate information, which can lead to faster diagnosis and treatment. POCT covers a wide range of testing methods and technologies, such as handheld electronics, test kits, and portable analyzers. Common examples are blood glucose monitoring, quick strep testing, and pregnancy tests. These devices can be used in a variety of venues, including hospitals, clinics, pharmacies, and even the home, making healthcare more accessible and efficient. POCT technology has grown tremendously, with downsizing and enhanced instrumentation increasing accuracy and ease of use.
The technological advancements is the driving factor that drives the market over the forecast period. For instance, Masimo announced that MightySat Medical has received FDA clearance, making it the first and only FDA-cleared medical fingertip pulse oximeter offered over-the-counter (OTC) to consumers without a prescription. This approval provides customers a pulse oximeter medical gadget powered by Masimo SET pulse oximetry, the same technology used by hospitals and clinics around the world to monitor over 200 million patients every year.
Market Dynamics: Drivers & Restraints
Technological advancements
The technological advancements is expected to be a significant factor in the growth of the global point-of-care testing devices market. Technological advances are expected to play a significant influence in the expansion of the global point-of-care testing (POCT) devices market. As healthcare evolves, there is an increasing need for quick, accurate, and accessible diagnostic solutions. Innovations in numerous technologies, including as biosensors, microfluidics, and lab-on-a-chip systems, have altered diagnostics, making them more efficient and reliable. For instance, in September 2024, Abbott Laboratories announced that its over-the-counter continuous glucose monitor Lingo is available in the U.S. One of Abbott's primary goals is to help Lingo users learn about glucose spikes, which occur when the amount of sugar present in the bloodstream rapidly increases and then decreases.
Moreover in August 2024, DEXIS Launched DEXIS Connect Pro, a New Proactive Service Platform for DEXIS CBCT and Intraoral Sensor Devices, Focused on Increasing Device Uptime. This unique platform uses Internet of Things (IoT) technology to continuously check the health of these devices, ensuring they run at peak performance. DEXIS Connect Pro seeks to significantly improve device uptime by automatically recognizing potential difficulties and arranging for support or equipment replacements as needed, which is crucial for dental offices that rely on consistent operation to provide patient care.
Moreover in April 2024, Bio-Rad Laboratories has launched its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay adds to the company's Droplet Digital PCR (ddPC) portfolio in the cancer industry, where extremely sensitive and multiplexed mutation detection assays enhance translational research, medication selection, and disease monitoring. These recent launches and FDA approvals along with latest technological advancements in them makes the diagnostic results efficient and quick which drives the market.
High initial investment costs
Factors such as high initial investment costs are expected to hamper the global point-of-care testing devices market. Although POCT provides various benefits, such as rapid results and the ability to test outside of traditional laboratory settings, the financial costs associated with procuring these devices may dissuade healthcare organizations from using them. The initial investment for POCT equipment might be significant, especially for advanced technologies that promise improved diagnostic capabilities. This financial burden is particularly acute in resource-constrained environments where healthcare funds are tight, making it difficult for facilities to prioritize investment in novel diagnostic methods.
The global point-of-care testing devices market is segmented based on product , application, testing type, distribution channel and region.
Glucose monitoring products segment is expected to dominate the global point-of-care testing devices market share
The glucose monitoring products segment is predicted to dominate the global point-of-care testing (POCT) devices market due to a number of compelling factors, including increased diabetes prevalence, technological improvements, and an increase in demand for rapid diagnostic solutions. Diabetes remains a huge public health challenge around the world, thus effective management strategies are more important than ever. The increasing prevalence is one of the major reasons for the dominance of this segment. For instance, according to the National Institute of Health, approximately 462 million individuals were affected by type 2 diabetes corresponding to 6.28% of the world's population.
In the recent times, there are launches and FDA approvals of glucose monitoring devices. For instance, in September 2024, Abbott Laboratories announced that its over-the-counter continuous glucose monitor Lingo is available in the U.S. One of Abbott's primary goals is to help Lingo users learn about glucose spikes, which occur when the amount of sugar present in the bloodstream rapidly increases and then decreases.
Moreover, in June 2024, Prevounce Health, a leading provider of remote care management software, devices, and services, announced the launch of its first remote blood glucose monitoring device, Pylo GL1-LTE. The blood glucose meter has been scientifically tested and linked to numerous cellular networks to guarantee more dependable data transmission across the United States. The GL1-LTE is compatible with the Prevounce remote care management platform and may be integrated with other health software using the Pylo cloud API. Prevounce's Pylo cellular-connected gadgets include blood pressure monitors and weight scales.
North America is expected to hold a significant position in the global point-of-care testing devices market share
North America is expected to hold a significant portion of the global point-of-care testing devices market. North America is projected to account for a significant portion of the global point-of-care testing (POCT) device market, owing to a mix of factors such as a strong healthcare infrastructure, rising chronic illness incidence, and technological improvements. The increased prevalence of chronic diseases, such as diabetes, cardiovascular problems, and infectious diseases, is a major driver of market expansion in North America. For instance, according to the Centers for Disease Control and Prevention, in 2024 more than 38 million Americans have diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes. Type 2 diabetes most often develops in people 45 or older, but more and more children, teens, and young adults are also developing it.
There are recent launches in this region due to the presence of major players. For instance, in September 2024, Abbott Laboratories announced that its over-the-counter continuous glucose monitor Lingo is available in the U.S. One of Abbott's primary goals is to help Lingo users learn about glucose spikes, which occur when the amount of sugar present in the bloodstream rapidly increases and then decreases.
Asia Pacific is growing at the fastest pace in the global point-of-care testing devices market
The Asia Pacific region is experiencing rapid growth in the global point-of-care testing (POCT) device market. Several significant factors contribute to this expansion, including rising healthcare costs, increased awareness of early disease diagnosis, and the demand for quick and precise diagnostic results. The need for POCT has increased as these devices have proven invaluable for the early diagnosis and monitoring of a variety of health disorders, thereby improving disease management results throughout the region.
There are recent launches of devices in this region making it the fastest growing region. For instance, in November 2023, UK-based LumiraDx Healthcare has launched its highly sensitive C-Reactive Protein (CRP) point of care (POC) antigen test across India. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance (AMR). From a tiny sample of finger-prick blood, the CRP test gives results within four minutes on the portable LumiraDx platform which weighs just over a kilogram.
The major global players in the global point-of-care testing devices market include Abbott, F. Hoffmann-La Roche, BD, Siemens Healthcare Private Limited, Bio-Rad Laboratories, Inc., Danaher Corporation, SEKISUI Diagnostics, Trinity Biotech, Beckman Coulter, Inc., Nova Biomedical among others.
Emerging Players
PocDoc, Biocode, Sense4Med among others
The global point-of-care testing devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE